Mer­ck breathes a sigh of re­lief as Keytru­da-Lenvi­ma com­bo aces con­fir­ma­to­ry study in en­dome­tri­al can­cer

Mer­ck has been in the FDA’s crosshairs over ac­cel­er­at­ed ap­provals for PD-(L)1 in­hibitor Keytru­da that have whiffed in con­fir­ma­to­ry stud­ies. One of those speedy nods, a pair­ing with TKI in­hibitor Lenvi­ma from Ei­sai in en­dome­tri­al can­cer, has now scored a much-need­ed OS win to back up its case.

The Keytru­da-Lenvi­ma com­bo nailed its pri­ma­ry pro­gres­sion-free sur­vival and OS end­points in an open-la­bel Phase III study in ad­vanced, metasta­t­ic or re­cur­rent en­dome­tri­al can­cer pa­tients af­ter chemother­a­py, ac­cord­ing to da­ta pre­sent­ed Fri­day at the vir­tu­al So­ci­ety of Gy­ne­co­log­ic On­col­o­gy an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER